Bisphosphonates Safe but May Not Improve Bone Marrow Lesion Volume
Priyanka Ballal, M.D., from the Boston Medical Center, and colleagues assessed the effect of oral bisphosphonates on BML volume over 12 months. Mean change in BML volume was compared between 145 women who newly initiated an oral bisphosphonate for knee osteoarthritis and propensity-matched noninitiators.
The researchers found that the difference in mean change in total BML volume between the two groups was not significant, regardless of the presence of baseline BMLs (P = 0.4, 95 percent confidence interval, −156.6 to +354.2). The two groups were similar with respect to the proportion of participants with decreased, increased, or unchanged BML volumes during the 12 months. Among individuals with baseline BMLs, the proportion of patients initiating bisphosphonates with a decrease in BML volume versus stable or increased BML volume was greater compared with noninitiators (P = 0.03).
"These results suggest that bisphosphonates do not appear to be harmful, at least over one year, and perhaps may even help decrease bone marrow lesions in those that have them," a coauthor said in a statement.
© 2020 HealthDay. All rights reserved.
Posted: August 2020
Read this next
TUESDAY, Sept. 15, 2020 -- For patients with knee osteoarthritis, Curcuma longa extract (CL) is more effective than placebo for knee pain but does not improve knee...
MONDAY, Aug. 3, 2020 -- Inhibition of interleukin-1β (IL-1β) with canakinumab seems to reduce the incidence of total hip replacement/total knee replacement (THR/TKR)...
MONDAY, July 13, 2020 -- The Norfolk Arthritis Register has released an interim report on the impact of COVID-19 restrictions on people living with inflammatory arthritis who were...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.